{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:38:50Z","timestamp":1791549530322,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK034854"],"award-info":[{"award-number":["P30 DK034854"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s11695-024-07178-5","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T11:02:22Z","timestamp":1711018942000},"page":"1471-1478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Combination Therapy of Endoscopic Gastric Remodeling with GLP-1RA for the Treatment of MASLD"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5273-6851","authenticated-orcid":false,"given":"Pichamol","family":"Jirapinyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aunchalee","family":"Jaroenlapnopparat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Zucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"7178_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol Baltim Md. 2016;64:73\u201384.","journal-title":"Hepatol Baltim Md"},{"key":"7178_CR2","doi-asserted-by":"publisher","first-page":"e0173499","DOI":"10.1371\/journal.pone.0173499","volume":"12","author":"MH Le","year":"2017","unstructured":"Le MH, Devaki P, Ha NB, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS ONE. 2017;12:e0173499.","journal-title":"PLoS ONE"},{"key":"7178_CR3","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","volume":"65","author":"R Pais","year":"2016","unstructured":"Pais R, Barritt AS, Calmus Y, et al. NAFLD and liver transplantation: current burden and expected challenges. J Hepatol. 2016;65:1245\u201357.","journal-title":"J Hepatol"},{"issue":"6","key":"7178_CR4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356.","journal-title":"J Hepatol."},{"key":"7178_CR5","doi-asserted-by":"publisher","first-page":"e0352","DOI":"10.1097\/HC9.0000000000000352","volume":"8","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Stepanova M, Al Shabeeb R, et al. The changing epidemiology of adult liver transplantation in the United States in 2013\u20132022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Hepatol Commun. 2024;8:e0352.","journal-title":"Hepatol Commun"},{"key":"7178_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-3783e5 (quiz e14-15).","journal-title":"Gastroenterology"},{"key":"7178_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","volume":"149","author":"G Lassailly","year":"2015","unstructured":"Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379\u201388 (quiz e15-16).","journal-title":"Gastroenterology"},{"key":"7178_CR8","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","volume":"401","author":"O Verrastro","year":"2023","unstructured":"Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet Lond Engl. 2023;401:1786\u201397.","journal-title":"Lancet Lond Engl"},{"key":"7178_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","volume":"33","author":"D Eisenberg","year":"2023","unstructured":"Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. Obes Surg. 2023;33:3\u201314.","journal-title":"Obes Surg"},{"key":"7178_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.soard.2018.10.005","volume":"15","author":"H Gasoyan","year":"2019","unstructured":"Gasoyan H, Tajeu G, Halpern MT, et al. Reasons for underutilization of bariatric surgery: the role of insurance benefit design. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2019;15:146\u201351.","journal-title":"Surg Obes Relat Dis Off J Am Soc Bariatr Surg"},{"issue":"6","key":"7178_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.14309\/ajg.0000000000002087","volume":"118","author":"P Jirapinyo","year":"2023","unstructured":"Jirapinyo P, Zucker SD, Thompson CC. Regression of hepatic fibrosis after endoscopic gastric plication in nonalcoholic fatty liver disease. Am J Gastroenterol. 2023;118(6):983\u201390.","journal-title":"Am J Gastroenterol."},{"key":"7178_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"7178_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/metabo11020073","volume":"11","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, et al. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021;11:73.","journal-title":"Metabolites"},{"key":"7178_CR14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatol Baltim Md. 2023;77:1797\u2013835.","journal-title":"Hepatol Baltim Md"},{"key":"7178_CR15","volume-title":"Endoscopic sleeve gastroplasty with anti-obesity medications: analysis of combination therapy, optimal timing and agents","author":"P Jirapinyo","year":"2023","unstructured":"Jirapinyo P, Jaroenlapnopparat A, Thompson CC. Endoscopic sleeve gastroplasty with anti-obesity medications: analysis of combination therapy, optimal timing and agents. Gastroenterology. 2023;164(6):S-145."},{"key":"7178_CR16","first-page":"296","volume":"3","author":"P Jirapinyo","year":"2018","unstructured":"Jirapinyo P, Thompson CC. Gastric plications for weight loss: distal primary obesity surgery endoluminal through a belt-and-suspenders approach. VideoGIE Off Video J Am Soc Gastrointest Endosc. 2018;3:296\u2013300.","journal-title":"VideoGIE Off Video J Am Soc Gastrointest Endosc"},{"key":"7178_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.gie.2022.04.1346","volume":"96","author":"P Jirapinyo","year":"2022","unstructured":"Jirapinyo P, Thompson CC. Comparison of distal primary obesity surgery endolumenal techniques for the treatment of obesity (with videos). Gastrointest Endosc. 2022;96:479\u201386.","journal-title":"Gastrointest Endosc"},{"key":"7178_CR18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","volume":"76","author":"ME Rinella","year":"2022","unstructured":"Rinella ME, Dufour J-F, Anstee QM, et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study. J Hepatol. 2022;76:536\u201348.","journal-title":"J Hepatol"},{"key":"7178_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/apt.12149","volume":"37","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther. 2013;37:234\u201342.","journal-title":"Aliment Pharmacol Ther"},{"key":"7178_CR20","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113\u201324.","journal-title":"N Engl J Med"},{"key":"7178_CR21","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1097\/CM9.0000000000000835","volume":"133","author":"Y-M Sun","year":"2020","unstructured":"Sun Y-M, Chen S-Y, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J (Engl). 2020;133:1696\u2013702.","journal-title":"Chin Med J (Engl)"},{"key":"7178_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511\u201322.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7178_CR23","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1007\/s11695-021-05289-x","volume":"31","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Pouwels S, Parmar C, et al. Outcomes of bariatric surgery in patients with liver cirrhosis: a systematic review. Obes Surg. 2021;31:2255\u201367.","journal-title":"Obes Surg"},{"key":"7178_CR24","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46:S140\u201357.","journal-title":"Diabetes Care"},{"key":"7178_CR25","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","volume":"69","author":"J-F Dufour","year":"2020","unstructured":"Dufour J-F, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut. 2020;69:1877\u201384.","journal-title":"Gut"},{"issue":"23","key":"7178_CR26","first-page":"02506","volume":"S0016\u20135107","author":"P Jirapinyo","year":"2023","unstructured":"Jirapinyo P, Thompson CC. Combining transoral outlet reduction with pharmacotherapy yields similar one-year efficacy with improved safety compared to surgical revision for weight regain following Roux-en-Y gastric bypass. Gastrointest Endosc. 2023;S0016\u20135107(23):02506\u201313.","journal-title":"Gastrointest Endosc"},{"key":"7178_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s11695-015-1863-8","volume":"26","author":"JC Espin\u00f3s","year":"2016","unstructured":"Espin\u00f3s JC, Turr\u00f3 R, Moragas G, et al. Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure. Obes Surg. 2016;26:1081\u20139.","journal-title":"Obes Surg"},{"key":"7178_CR28","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131\u201357.","journal-title":"Gastroenterology"},{"key":"7178_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/5584_2020_496","volume":"1307","author":"DB Maselli","year":"2021","unstructured":"Maselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021;1307:171\u201392.","journal-title":"Adv Exp Med Biol"},{"key":"7178_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","volume":"156","author":"R Loomba","year":"2019","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, et al. Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis. Gastroenterology. 2019;156:88-95.e5.","journal-title":"Gastroenterology"},{"key":"7178_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fphar.2016.00159","volume":"7","author":"JL Chin","year":"2016","unstructured":"Chin JL, Pavlides M, Moolla A, et al. Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy? Front Pharmacol. 2016;7:159.","journal-title":"Front Pharmacol"},{"key":"7178_CR32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","volume":"76","author":"J Boursier","year":"2022","unstructured":"Boursier J, Hagstr\u00f6m H, Ekstedt M, et al. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. J Hepatol. 2022;76:1013\u201320.","journal-title":"J Hepatol"},{"key":"7178_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1148\/radiol.2016160685","volume":"283","author":"J Chen","year":"2017","unstructured":"Chen J, Yin M, Talwalkar JA, et al. Diagnostic performance of MR elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity. Radiology. 2017;283:418\u201328.","journal-title":"Radiology"}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-024-07178-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11695-024-07178-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-024-07178-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T13:23:40Z","timestamp":1713533020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11695-024-07178-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["7178"],"URL":"https:\/\/doi.org\/10.1007\/s11695-024-07178-5","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"value":"0960-8923","type":"print"},{"value":"1708-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Informed consent does not apply.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Pichamol Jirapinyo, MD, has received research support from Apollo Endosurgery, Boston Scientific, Fractyl, GI Dynamics and USGI Medical; has served as a consultant to Apollo Endosurgery, ERBE, GI Dynamics and Spatz Medical; and has received royalty from Endosim.Christopher C. Thompson, MD, has served as a consultant for Apollo Endosurgery, Boston Scientific, Endoquest Robotics, Enterasense, EnVision Endoscopy, Fractyl, USGI Medical, Medtronic\/Covidien, Olympus\/Spiration, GI Dynamics, and Xenter; has served as an advisory boards member for USGI Medical and Fractyl; has received research grant and support from USGI Medical, Apollo Endosurgery, Boston Scientific, Endoquest Robotics, ERBE, FujiFilm, Lumendi Olympus\/Spiration, Aspire Bariatrics and GI Dynamics; has served as a general partners for Blueframe Healthcare; has served as a founder for Enterasense, EnVision Endoscopy and GI Windows; and holds stock and royalties for GI Windows.Aunchalee Jaroenlapnopparat, MD and Stephen D. Zucker, MD have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}